The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2026
Consensus statement of dienogest as a progestin in contraception and non-contraceptive clinical entities (heavy menstrual bleeding, acne and hirsutism). Narrative review of the literature and recent developments.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Grandi Giovanni, Nappi Rossella E, Cagnacci Angelo, Bruni Vincenzina, Bettoli Vincenzo, Gambera Alessandro, Favalli Filippo, Colli Enrico, Regidor Pedro-Antonio
Аннотация
BACKGROUND: Combined oral contraceptives (COC)s, besides offering a reliable and safe contraception, offer a variety of non-contraceptive health benefits and therapeutic positive aspects.
METHODS: While contraceptive use is the primary indication for COC use, a variety of medical conditions have been added in the summary of product characteristics (SmPC) of these formulations.
RESULTS: Dienogest, a 17a-cyanomethyl-17ß-hydroxy-4,9-estradien-3-one progestin is used in different dosage regimes with different oestrogens and with different release forms in contraception and has, depending on the type of COC additional medical treatment indications.
CONCLUSIONS: This narrative review will focus on the effects, apart from contraception, of these COCs on female target organs like the uterus and the skin and clinical entities as the polycystic ovarian syndrome (PCOS).
METHODS: While contraceptive use is the primary indication for COC use, a variety of medical conditions have been added in the summary of product characteristics (SmPC) of these formulations.
RESULTS: Dienogest, a 17a-cyanomethyl-17ß-hydroxy-4,9-estradien-3-one progestin is used in different dosage regimes with different oestrogens and with different release forms in contraception and has, depending on the type of COC additional medical treatment indications.
CONCLUSIONS: This narrative review will focus on the effects, apart from contraception, of these COCs on female target organs like the uterus and the skin and clinical entities as the polycystic ovarian syndrome (PCOS).